macugen
FDA Announces Advisory Committee Meeting Date for Macugen (pegaptanib sodium injection)
NEW YORK, May 26, 2004 -- Eyetech Pharmaceuticals, Inc macugen. (Nasdaq: EYET) a biopharmaceuticalcompany that specializes in the development and commercialization of novel therapeuticsto treat diseases of the eye, has learned today that the Food and Drug Administrationhas announced the forthcoming meeting of a public advisory committee of theFDA to discuss the new drug application 21-756, pegaptanib sodium injection(proposed trade name, Macugen) by Eyetech Pharmaceuticals, Inc., indicated forthe treatment of exudative (wet) age-related macular degeneration to be heldon August 27, 2004 at 8:00 AM EDT at FDA in Rockville, Maryland. About Eyetech Pharmaceuticals, Inc.
Eyetech Pharmaceuticals, Inc macugen. is a biopharmaceutical company that specializesin the development and commercialization of novel therapeutics to treat diseasesof the eye macugen. Eyetech's initial focus is on diseases affecting the back of theeye macugen. The company's most advanced product candidate is Macugen (pegaptanib sodiuminjection), which Eyetech is developing with Pfizer Inc for the prevention andtreatment of diseases of the eye and related conditions macugen. Eyetech's lead clinicaltrials include two phase 2/3 pivotal clinical trials for the use of Macugenin the treatment of the wet form of age-related macular degeneration and a phase2 clinical trial for the use of Macugen for the treatment of diabetic macularedema.
|
